Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/264386
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters

AutorBoudewijns, Robbert; Pérez, Patricia; Lázaro-Frías, Adrián; Van Looveren, Dominique; Vercruysse, Thomas; Thibaut, Hendrik Jan; Weynand, Birgit; Coelmont, Lotte; Neyts, Johan; Astorgano, David; Montenegro, Dolores; Puentes, Eugenia; Rodríguez, Esteban; Dallmeier, Kai; Esteban, Mariano CSIC ORCID ; García-Arriaza, Juan CSIC ORCID
Palabras claveSARS-CoV-2
COVID-19
MVA vaccine
Spike
Hamsters
Immunogenicity
Efficacy
Fecha de publicación16-mar-2022
EditorFrontiers Media
CitaciónFrontiers in Immunology 13: 845969 (2022)
ResumenTo control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector expressing a human codon optimized full-length SARS-CoV-2 spike (S) protein (MVA-S). Immunization with one or two doses of MVA-S elicited high titers of S- and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against parental SARS-CoV-2 and VoC alpha, beta, gamma, delta, and omicron. After SARS-CoV-2 challenge, MVA-S-vaccinated hamsters showed a significantly strong reduction of viral RNA and infectious virus in the lungs compared to the MVA-WT control group. Moreover, a marked reduction in lung histopathology was also observed in MVA-S-vaccinated hamsters. These results favor the use of MVA-S as a potential vaccine candidate for SARS-CoV-2 in clinical trials.
Versión del editorhttps://doi.org/10.3389/fimmu.2022.845969
URIhttp://hdl.handle.net/10261/264386
DOI10.3389/fimmu.2022.845969
E-ISSN1664-3224
Aparece en las colecciones: (PTI Salud Global) Colección Especial COVID-19
(CNB) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
fimmu-13-845969.pdf8,38 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

13
checked on 29-mar-2024

WEB OF SCIENCETM
Citations

13
checked on 22-feb-2024

Page view(s)

93
checked on 29-mar-2024

Download(s)

63
checked on 29-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Este item está licenciado bajo una Licencia Creative Commons Creative Commons